Skip to main content
Premium Trial:

Request an Annual Quote

Philips and Organon Will Use Imaging Technology in Biomarker Research

NEW YORK (GenomeWeb News) — Philips Life Sciences and Organon will perform biomarker studies that could benefit Philips’ imaging programs and Organon's drug-development efforts, the companies said yesterday.
Under the agreement, researchers from both companies will use Philips' labs and medical-imaging technologies to identify, validate, and pursue uses for novel biomarkers that Organon may use to develop drug programs for psychiatric and immune system disorders.
The companies said the research will be conducted at Philips' High Tech Campus in Eindhoven, the Netherlands.
Rick Harwig, Philips’ chief technology officer, said his company's imaging modalities are improving "to image the function and behavior of an anatomical feature, and not just its shape."
Harwig said working with Organon will help Philips "speed the evolution" of its imaging technology "into tools to image the body at the molecular level."

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.